Tin tứcTổng quan thị trườngRegeneron beats quarterly profit estimates on Eylea strength

Regeneron beats quarterly profit estimates on Eylea strength

(Reuters) – Regeneron Pharmaceuticals Inc (NASDAQ:REGN) beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for its blockbuster eye drug Eylea and eczema treatment Dupixent.

Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts’ estimates of $9.56, according to Refinitiv data.

NHỮNG BÀI VIẾT LIÊN QUAN
băng hình
chơi-tròn-điền

Phổ biến nhất